22812-50-6

Basic information

• Product Name: A-NAPHTHOFLAVONOL
• Synonyms: ALPHA-NAPHTHOFLAVANOL;A-NAPHTHOFLAVONOL
• CAS NO: 22812-50-6
• Molecular Formula: C₁₉H₁₂O₃
• Molecular Weight: 288.3
• Product Categories: Flavanols
• Mol File: 22812-50-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: A-NAPHTHOFLAVONOL(CAS DataBase Reference)
• NIST Chemistry Reference: A-NAPHTHOFLAVONOL(22812-50-6)
• EPA Substance Registry System: A-NAPHTHOFLAVONOL(22812-50-6)

Safety Data

• Hazardous Substances Data: 22812-50-6(Hazardous Substances Data)

Upstream product

• 711-79-5 1-hydroxy-2-acetonaphthone 
• 100-52-7 benzaldehyde 
• 125574-15-4 (E)-1-(1-hydroxynaphthalen-2-yl)-3-phenylprop-2-en-1-one 
• 604-59-1 α-naphtoflavone 
• 98314-96-6 (2S,3R)-2,4,4-Trimethoxy-2-phenyl-3,4-dihydro-2H-benzo[h]chromen-3-ol 

Downstream Products

• 1456866-17-3 3-methoxy-2-phenyl-4H-benzo[h]chromen-4-one 
• 22825-62-3 3-acetoxy-2-phenyl-benzo[h]chromen-4-one 
• 105866-24-8 2,3-dimethoxy-3-hydroxy-α-naphthoflavanone 

Relevant articles and documents

An enzyme-responsive and photoactivatable carbon-monoxide releasing molecule for bacterial infection theranostics

Infections caused by pathogenic bacteria, especially the drug-resistant bacteria, are posing a devastating threat to public health, which underscores the urgent needs for advanced strategies to effectively prevent and treat these intractable issues. Here

Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2

Multidrug resistance (MDR) often leads to a failure of cancer chemotherapy. Breast Cancer Resistance Protein (BCRP/ABCG2), a member of the superfamily of ATP binding cassette proteins has been found to confer MDR in cancer cells by transporting molecules with amphiphilic character out of the cells using energy from ATP hydrolysis. Inhibiting BCRP can be a solution to overcome MDR.We synthesized a series of flavones, 7,8-benzofl avones and 5,6-benzo flavones with varying substituents at positions 3, 3′ and 4′ of the (benzo)fl avone structure. All synthesized compounds were tested for BCRP inhibition in Hoechst 33342 and pheophorbide A accumulation assays using MDCK cells expressing BCRP. All the compounds were further screened for their P-glycoprotein (P-gp) and Multidrug resistance-associated protein 1 (MRP1) inhibitory activity by calcein AM accumulation assay to check the selectivity towards BCRP. In addition most active compounds were investigated for their cytotoxicity. It was observed that in most cases 7,8-benzoflavones are more potent in comparison to the 5,6-benzoflavones. In general it was found that presence of a 3-OCH3 substituent leads to increase in activity in comparison to presence of OH or no substitution at position 3. Also, it was found that presence of 3′,4′-OCH3 on phenyl ring lead to increase in activity as compared to other substituents. Compound 24, a 7,8-benzoflavone derivative was found to be most potent being 50 times selective for BCRP and showing very low cytotoxicity at higher concentrations.